393 completed, 87 terminated, 78 unknown, 58 recruiting. 443 Phase 2, 205 Phase 1, 107 Phase 3, 37 Not applicable, 7 Early Phase 1.
Follow this drug Literature Review of Melphalan trials Research Report on Melphalan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 6 | 2027-01-31 | 2026-09-09 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome Busulfan, Melphalan, Fludarabine - Myelodysplastic Syndromes, Graft Vs Host Disease | Not applicable | Not yet recruiting | Guenther Koehne | 62 | 2027-01-01 | 2026-10-13 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 18 | 2027-01-01 | 2026-09-09 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-10-01 | 2026-09-29 |
| A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). AZD0120, Cyclophosphamide, Fludarabine - Newly Diagnosed Multiple Myeloma (NDMM) | Phase 3 | Recruiting | AstraZeneca | 750 | 2026-09-24 | 2026-10-21 |
| D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Isatuximab, Iberdomide, Bortezomib (B) - Multiple Myeloma | Phase 3 | Recruiting | Dana-Farber Cancer Institute | 720 | 2026-08-31 | 2026-10-09 |
| Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen - AML (Acute Myelogenous Leukemia), Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2026-07-20 | 2026-06-12 |
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-07-01 |
| Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors Gemcitabine (GEM), Docetaxel, Melphalan - Prospective Observational Study, Gemcitabine | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-06-05 | 2026-06-23 | |
| Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial Thiotepa and Melphalan, Melphalan - Multiple Myeloma | Not applicable | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 204 | 2026-04-20 | 2026-04-21 |
| ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse TEAM regimen (thiotepa, etoposide, cytarabine and melphalan) - Lymphoma Patients With High-risk of Central Nervous System Relapse | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-03-01 | 2026-03-19 |
| Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan - Venentoclax, Myeloid Malignancies | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 186 | 2026-03-01 | 2026-03-17 |
| Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan - Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-02-04 | 2026-10-19 |
| Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation Treosulfan (Treo), Melphalan (Mel), Fludarabine (Flud) - AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Technische Universität Dresden | 220 | 2026-01-21 | 2026-09-02 |
Showing 20 of 716. Sign in to see all of them.
Multiple Myeloma (253) · Lymphoma (128) · Leukemia, Myeloid, Acute (104) · Lymphoma, Non-Hodgkin (98) · Myelodysplastic Syndromes (96) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (93) · Neoplasms, Plasma Cell (91) · Leukemia (79) · Hodgkin Disease (78) · Lymphoma, Large B-Cell, Diffuse (66) · Leukemia, Lymphocytic, Chronic, B-Cell (65) · Lymphoma, Mantle-Cell (59) · Lymphoma, Follicular (57) · Burkitt Lymphoma (44) · Neuroblastoma (44)
M.D. Anderson Cancer Center (65) · City of Hope Medical Center (37) · Fred Hutchinson Cancer Center (30) · Memorial Sloan Kettering Cancer Center (30) · National Cancer Institute (NCI) (24) · Masonic Cancer Center, University of Minnesota (19) · St. Jude Children's Research Hospital (16) · Children's Oncology Group (14) · University of Arkansas (13) · Washington University School of Medicine (13) · Roswell Park Cancer Institute (11) · Weill Medical College of Cornell University (10) · Mayo Clinic (9) · SWOG Cancer Research Network (9) · University of Maryland, Baltimore (9)
United States (522) · Italy (38) · France (36) · United Kingdom (35) · China (32) · Germany (32) · Spain (29) · Canada (28) · Australia (24) · Belgium (24) · Switzerland (24) · South Korea (20) · Czechia (18) · Austria (17) · Netherlands (16)
Brandon Triplett, MD (8) · Vaishali Sanchorawala, MD (7) · William I. Bensinger, MD (7) · Yago Nieto, MD, PHD (7) · George Somlo, MD (5) · Mario Boccadoro, MD (5) · Mary Horowitz, MD (5) · Muzaffar H. Qazilbash, MD (5) · Barry R. Meisenberg, MD (4) · Frank Berthold, MD (4) · H. Richard Alexander, MD, FACS (4) · Morie A. Gertz, MD (4) · Aaron P. Rapoport, MD (3) · Andrew Artz, MD (3)
PMID 31221778, PMID 29567784, PMID 33357481, PMID 22689675, PMID 32499241, PMID 33951890, PMID 40501401, PMID 20567002, PMID 25628469, PMID 27465021, PMID 28380315, PMID 29675792, PMID 30561775, PMID 31248973, PMID 34028986, PMID 34515338, PMID 36240296, PMID 36882409, PMID 10084252, PMID 10414913, PMID 10414914, PMID 10459351, PMID 10482933, PMID 10797354, PMID 10918404, PMID 11015443, PMID 11313690, PMID 11464889, PMID 11869699, PMID 11904735, PMID 12101494, PMID 12242449, PMID 12569285, PMID 12721664, PMID 12932669, PMID 14673042, PMID 14767498, PMID 15156165, PMID 15297412, PMID 15800326, PMID 16313258, PMID 16421427, PMID 16432076, PMID 16525139, PMID 16572419, PMID 16826357, PMID 16888080, PMID 16966258, PMID 17203752, PMID 17213292
P30CA033572 (21), P30CA015704 (10), U10CA180886 (10), P30CA015083 (8), U10CA032102 (8), P30CA016672 (5), U01HL069294 (5), U10CA098543 (5), U10CA180821 (5), 2009 (4), P01CA030206 (4), P30CA022453 (4), U10CA021115 (4), U10CA031946 (4), P01CA081403 (3)